It's an interesting option. When it will return to favour is anyones guess but it certainly isn't overpriced at these levels.
The independent review might mark the turning point (presuming it's decent)
Always amazed that larger companies e.g. Devon don't just wipe up these little messes when they hit these kind of levels... Suppose there is only so much exposure they can tolerate.
- Forums
- ASX - By Stock
- a trade perhaps soon
THK
unknown
It's an interesting option. When it will return to favour is...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online